(Date:6/18/2013)... -- RegeneCure announced today the start ... Bone Regeneration (GBR) Dental Membrane as a bone stimulating aid ... encountered when patients have a tooth replaced with a dental ... the implant. Consequently there is often a need to support ... regenerates. The bone substitute material, in turn, needs to be ...
(Date:6/18/2013)... June 18, 2013 The "Bioinformatics Market By ... Knowledge Management Tools & Data Analysis Services) & Application (Genomics, ... the Major Market Drivers, Restraints, and Opportunities in ... Asia-Pacific and Rest of World. ... 22 Figures 364 ...
(Date:6/18/2013)... , June 18, 2013 ... ) has announced the addition of the ... [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & ... & Auto Injectors] & Therapeutics [Diabetes & ... report to their offering. ...
(Date:6/18/2013)... Inflamax Research Inc., a full ... Phase I-IV clinical trials, announced today that they ... Environmental Technologies (NAET), a specialty air conditioning & ... servicing of mobile Environmental Exposure Chambers (EECs) used ... , Inflamax Research has proprietary Next ...
Breaking Biology Technology:RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3... Eastern Time -, SAN FRANCISCO, Nov. 10 ... corporate progress and financial,results for the quarter ended September ... of significant,achievement and progress and was capped with the ... collaboration not only gives us,access to a world-class partner ...
... Conference Call Today To Discuss the Data and Ongoing ... Clinical Development Programs, ... announced today top-line data from its,SB-509-601 clinical trial, one of Sangamo,s ... SB-509 for diabetic,neuropathy (DN). The data demonstrate that repeat administration of ...
... Divestitures of Non-Core Product Lines -, HOPKINTON, ... CALP ) today reported third quarter financial,results ... line divestitures: the,sale of its AutoTrace(R) product line ... of its Pharmaceutical Development and Quality Analysis,(PDQ) product ...
Cached Biology Technology:Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 2Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 3Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 4Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 5Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 6Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 7Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 8Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 2Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 3Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 4Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 5Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 6Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 2Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 3Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 4Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 5Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 6Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 7Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 8Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 9Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 10Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 11Blue Standard is 3-cyano-7-hydroxycoumarin....
Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...
6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE)...
Endothelin-converting enzyme 1 (EC 3.4.24.71) (ECE-1). [Source:Uniprot/SWISSPROT;Acc:P42892] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products:Biology NavigationMedical Navigation